Navigation Links
MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
Date:9/10/2013

ry and pre-clinical development of PWT143 to date," said Julie Cherrington, Ph.D., President and Chief Executive Officer of Pathway Therapeutics. "We continue to believe strongly in its potential to be an important drug for patients, and we are pleased that it is going into the hands of a team with the resources and drug development expertise to maximize that potential."

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor being developed for advanced hematologic diseases, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in combination with Vidaza (azacitidine) in patients with MDS presented at the American Society of Hematology Annual Meeting in December 2012 showed an overall response rate of 89% (eight out of nine). In June 2013, the Company initiated a randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza in patients with previously untreated MDS. An open-label Phase II trial of Pracinostat in combination with Vidaza in elderly patients with AML unsuitable for induction therapy is expected to initiate in the fall of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a first-in-human Phase I trial of ME-344 in patients with solid refractory tumors are anticipated in October 2013. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe a
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
3. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
4. Pharmaceutical Giants Back Researchers in Unique US Competition
5. Several Market Access Drivers Provide Attractive Opportunities for Multinational Companies in Saudi Arabias Pharmaceutical Market
6. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
7. Sunshine Act 2013 Updates: A Checklist for Pharmaceutical Companies to Meet CMS Reporting
8. PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
9. Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
10. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
11. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 The National Association of Managed ... released the NAMCP Medical Technologies Dossier Template © ... © , which provide medical directors and manufacturers ... devices or diagnostics that accounts for evidence-based development ... technology types (instead of having to attempt to ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... Alberta , Sept. 16, 2014  Wearable ... billion industry in less than two years, producing ... the way. A huge opportunity exists for leveraging ... Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind wearable ... based on years of clinical research linking activity ...
Breaking Medicine Technology:NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3
... Mass., Oct. 26 DUSA Pharmaceuticals, Inc.® (Nasdaq: ... dermatology announced today that it has been named to ... consecutive year, Deloitte recognized DUSA as one of the ... and clean technology companies in North America.  Rankings are ...
... Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop... -- INGELHEIM, Germany and ROCKVILLE, Md., Oct. 26 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:DUSA Pharmaceuticals Named to Deloitte's 2010 Technology Fast 500 List of Fastest Growing Companies in North America 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 3Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 4Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 5Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 6Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 7Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 8Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 9Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 10
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Almost all the ... in veins are equally safe and effective, new ... effectiveness of treatments for such blood clots as ... in a lung), Canadian researchers analyzed outcomes associated ... heparin (LMWH) and fondaparinux in combination with vitamin ...
(Date:9/16/2014)... Dennis Thompson HealthDay ... -- A combination drug therapy aimed at opening the ... treatment for older adults with chronic obstructive pulmonary disease ... COPD patients who received a combination of ... to die or require hospitalization because of their breathing ...
(Date:9/16/2014)... York (PRWEB) September 16, 2014 ... filed against C.R. Bard, Inc. continue to move ... U.S. District Court, Southern District of West Virginia, ... dated September 15, 2014, the Court has determined ... to the proceeding. The Order indicates that the ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Novatus, a ... a new office in London, UK, and appointed Jim ... in Europe, the expansion will allow Novatus to target ... its European customers. , “Novatus is ... and London is an ideal location to establish our ...
(Date:9/16/2014)... The child molestation victim lawyers at Estey ... who, according to case documents, were allegedly sexually abused ... San Diego. The victims were allegedly in elementary school ... of the defendant in the case remains confidential, per ... noted that no criminal charges were filed against the ...
Breaking Medicine News(10 mins):Health News: Most Treatments for Blood Clots Appear Safe, Effective 2Health News:Combo Therapy Best for COPD: Study 2Health News:Combo Therapy Best for COPD: Study 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Novatus Expands European Operations with a New Office in London 2Health News:ESTEY BOMBERGER Announces $3 Million Settlement for Sexual Abuse at San Diego Private School 2
... , SEATTLE, Aug. 24 Cell Therapeutics, Inc. (CTI) ... Drug Administration (FDA) has accepted and has filed for review the ... or refractory aggressive non-Hodgkin,s lymphoma (NHL). A Prescription Drug User Fee ... review of the pixantrone NDA by September 4th 2009. ...
... at the time of diagnosis do not live as long ... conclusion of a new study to be published in the ... journal of the American Cancer Society. The authors of the ... marital separation may compromise an individual,s immune system and lead ...
... factor for active tuberculosis (TB) disease, according to a new ... analyzed data from nearly 17,000 individuals in Taiwan as part ... past studies have reported increased mortality among TB patients who ... effect of smoking on active TB incidence using a longitudinal ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Over one-hundred business ... , ... -- Rooted in Newtonian and quantum science, ancient spiritual and healing traditions, and clinical studies, ... book ColorAlchemy , by Jami Lin teaches people how to harness a daily color ...
... diagnosis of Idiopathic Pulmonary Fibrosis is not much better ... the survival rate is less than three years. ... that targeting of a novel gene utilizing genetic and ... mice and will be developed for future testing in ...
Cached Medicine News:Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 2Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 3Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:Smoking increases risk of developing active TB 2Health News:Smoking increases risk of developing active TB 3Health News:New technique can help diagnose mesothelioma 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 3Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 4Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2
... System is a point-of-care system designed for ... referred to as Platelet Rich Plasma - ... a small sample of blood. The Symphony ... factors, which are found in the platelets. ...
... Dual Imaging Color Module Leica combines precision microscopy ... important and necessary patient data can be displayed ... optical platform on the Leica OH3, OHS1, MS3 ... highest brightness, contrast >300:1, true color and resolution ...
... Headlight mounted micro video camera has ... pictures in areas otherwise invisible to all ... capabilities. The system may be used for ... eliminating crowding of the sterile area and ...
... DXC-S500 consists of 2-piece body, one is CHU ... and built-in Peltier cooling devices, the other is ... monitor. CCU incorporates IEEE1394 interface for direct connection ... card slot for storing images into memory stick ...
Medicine Products: